Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T07:47:24.786Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients

A 90-day placebo-controlled dose-finding study

Published online by Cambridge University Press:  03 January 2018

I. Pelc ,
P. Verbanck ,
O. Le Bon ,
M. Gavrilovic ,
K. Lion  and
P. Lehert
I. Pelc*
Affiliation:
Brugmann University Hospital, Brussels, Belgium
P. Verbanck
Affiliation:
Brugmann University Hospital, Brussels, Belgium
O. Le Bon
Affiliation:
Brugmann University Hospital, Brussels, Belgium
M. Gavrilovic
Affiliation:
Brugmann University Hospital, Brussels, Belgium
K. Lion
Affiliation:
Brugmann University Hospital, Brussels, Belgium
P. Lehert
Affiliation:
Facultés Universitaires Catholiques de Mons, Mons, Belgium
*
Dr P. Verbanck, Psychiatry Department, Brugmann University Hospital, Van Gehuchten Place 4, 1020 Brussels, Belgium
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.

Method

In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day).

Results

For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.

Conclusion

This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.

Type
Papers
Information
The British Journal of Psychiatry , Volume 171 , Issue 1 , July 1997 , pp. 73 - 77
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington. DC: APA.Google Scholar
Daoust, M., Legrand, B., Gewiss, M., et al (1992) Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacology, Biochemistry and Behaviour, 41, 669–674.CrossRefGoogle ScholarPubMed
De Soto, C. B., O'Donnel, W. E. & De Soto, J. L. (1989) Long term recovery in alcoholics. Alcoholism: Clinical and Experimental Research, 13, 693–697.CrossRefGoogle ScholarPubMed
Gewiss, M., Heidbredder, C., Opsomer, L., et al (1991) Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol and Alcoholism, 26, 129–137.CrossRefGoogle ScholarPubMed
Gilbert, G. S. (1987) The effect of type of aftercare follow-up on treatment outcome among alcoholics. Journal of Studies on Alcohol, 49, 149–159.CrossRefGoogle Scholar
Guy, W. (ed.) (1974) ECDEU Assessment Manual for Psycho-pharmacology (3rd edn). Rockville, MD: National Institute of Mental Health.Google Scholar
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.CrossRefGoogle ScholarPubMed
Hamilton, M. (1960) Rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 93, 56–61.CrossRefGoogle Scholar
Lehert, P. (1993) Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol and Alcoholism, suppl. 2, 157–163.Google Scholar
Verbanck, P. (1995) The pharmacological treatment of alcoholism. From basic science to clinical medicine. Alcohol and Alcoholism, 30, 757–764.Google ScholarPubMed
Volpicelli, J. R., Alterman, A. I., Hayashida, M., et al (1992) Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876–880.CrossRefGoogle ScholarPubMed
Whitworth, A., Fischer, F., Letch, O. M., et al (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet, 347, 1438–1442.CrossRefGoogle ScholarPubMed
Zeise, M. L., Kasparow, S., Capogna, M., et al (1990) Calciumdiacetylhomotaurinate (Ca-aota) decreases the action of excitatory amino acids in the rat neocortex in vitro. Progress in Clinical Biological Research, 351, 237–242.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.